Anhui Anke Biotechnology Group Co Ltd
SZSE:300009

Watchlist Manager
Anhui Anke Biotechnology Group Co Ltd Logo
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Watchlist
Price: 8.27 CNY 1.35% Market Closed
Market Cap: 13.8B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Anhui Anke Biotechnology Group Co Ltd

Wall Street analysts forecast Anhui Anke Biotechnology Group Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Anhui Anke Biotechnology Group Co Ltd is 11 CNY with a low forecast of 10.89 CNY and a high forecast of 11.32 CNY.

Lowest Forecast
Wall Street Target
10.89 CNY
32% Upside
Average Forecast
Wall Street Target
11 CNY
33% Upside
Highest Forecast
Wall Street Target
11.32 CNY
37% Upside
Lowest
Price Target
10.89 CNY
32% Upside
Average
Price Target
11 CNY
33% Upside
Highest
Price Target
11.32 CNY
37% Upside
Anhui Anke Biotechnology Group Co Ltd Competitors:
Price Targets
300896
Imeik Technology Development Co Ltd
37% Upside
TVTX
Travere Therapeutics Inc
72% Upside
GRAL
Grail Inc
18% Downside
688331
RemeGen Co Ltd
21% Downside
300896
Imeik Technology Development Co Ltd
37% Upside
TVTX
Travere Therapeutics Inc
72% Upside
GRAL
Grail Inc
18% Downside
688331
RemeGen Co Ltd
21% Downside
ALT
Altimmune Inc
343% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
6% Downside
SNDX
Syndax Pharmaceuticals Inc
233% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
30% Upside

Revenue
Forecast

Revenue Estimate
Anhui Anke Biotechnology Group Co Ltd

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's revenue is 15%. The projected CAGR for the next 2 years is 27%.

15%
Past Growth
27%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Anhui Anke Biotechnology Group Co Ltd

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's operating income is 18%. The projected CAGR for the next 2 years is 33%.

18%
Past Growth
33%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Anhui Anke Biotechnology Group Co Ltd

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's net income is 17%. The projected CAGR for the next 2 years is 30%.

17%
Past Growth
30%
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Anhui Anke Biotechnology Group Co Ltd's stock price target?
Price Target
11 CNY

According to Wall Street analysts, the average 1-year price target for Anhui Anke Biotechnology Group Co Ltd is 11 CNY with a low forecast of 10.89 CNY and a high forecast of 11.32 CNY.

What is Anhui Anke Biotechnology Group Co Ltd's Revenue forecast?
Projected CAGR
27%

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's revenue is 15%. The projected CAGR for the next 2 years is 27%.

What is Anhui Anke Biotechnology Group Co Ltd's Operating Income forecast?
Projected CAGR
33%

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's operating income is 18%. The projected CAGR for the next 2 years is 33%.

What is Anhui Anke Biotechnology Group Co Ltd's Net Income forecast?
Projected CAGR
30%

For the last 8 years the compound annual growth rate for Anhui Anke Biotechnology Group Co Ltd's net income is 17%. The projected CAGR for the next 2 years is 30%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 253,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.